Gan & Lee在中国的bofanglutide试验中测试肥胖成人每月体重损失维持情况。 Gan & Lee's bofanglutide trial in China tests monthly weight loss maintenance in obese adults.

Gan & Lee制药公司已开始GRADUAL-3, 第三阶段试验在中国进行, 针对肥胖或超重成人的体重管理, Gan & Lee Pharmaceuticals has started GRADUAL-3, the third Phase 3 trial in China for its once-monthly GLP-1 receptor agonist bofanglutide, targeting weight management in adults with obesity or overweight. 这项研究由Linong Ji教授牵头,将评估药物在经过24周的治疗后保持体重下降的能力,每四个星期通过注射注射一次。 Led by Professor Linong Ji, the study will evaluate the drug’s ability to maintain weight loss after 24 weeks of treatment, with dosing every four weeks via subcutaneous injection. 试验是在较早的第三阶段研究之后进行的,这些研究显示,体重损失和新陈代谢效益相当大,包括与硫酸锡的比较。 The trial follows earlier Phase 3 studies showing significant weight loss and metabolic benefits, including a comparison with semaglutide. 目的是确认bofanglutide的有效性,安全性和长期依附潜力. The GRADUAL program, involving over 1,000 participants, aims to confirm bofanglutide’s efficacy, safety, and long-term adherence potential. 研制这种药物是为了治疗肥胖症、超重和2型糖尿病,其数据表明对降低葡萄糖的影响很大。 The drug is being developed for obesity, overweight, and type 2 diabetes, with data indicating strong glucose-lowering effects.